Drug Profile
Research programme: ADAM inhibitors - Incyte
Alternative Names: A disintegrin and metalloproteinase inhibitors - Incyte; HER-2 sheddase inhibitors - Incyte; INCB 3619Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Hydroxamic acids; Piperidines; Sulfonamides
- Mechanism of Action Epidermal growth factor inhibitors; Metalloprotease inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 03 Sep 2007 Data presented at the 234th American Chemical Society National Meeting (234th-ACS-2007) pharmacodynamics section
- 19 Jan 2006 Data presented at the 28th Annual San Antonio Breast Cancer Symposium (SABCS-2005) have been added to the adverse events and Cancer pharmacodynamics section